Fluorodeoxyglucose PET in relapsing polychondritis [12]

New England Journal of Medicine

Volumn 358, Issue 5, 2008, Pages 536-537

  De Geeter, Frank ^a   Vandecasteele, Stefaan J ^a  

^a Saint John's General Hospital   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DAPSONE; FLUORODEOXYGLUCOSE; METHYLPREDNISOLONE;

AGED; ANAMNESIS; ASTHMA; CARTILAGE BIOPSY; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSING POLYCHONDRITIS;

EID: 38749153554     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072254     Document Type: Letter

References (4)

1. Gergely P Jr, Poór G. Relapsing polychondritis. Best Pract Res Clin Rheumatol 2004;18:723-38.
2. Blockmans D, Knockaert D, Maes A, et al. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001;32:191-6.
3. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007;34:694-703.
4. Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674-81.